BCYC
Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel drug modality called Bicycle molecules—fully synthetic short peptides with two constrained loops that enable high-affinity binding to disease targets while maintaining small-molecule manufacturing and pharmacokinetic properties. The company uses a proprietary phage display screening platform to identify Bicycle molecules and is currently focused on oncology, with its lead candidate nuzefatide pevedotin (a Bicycle Drug Conjugate that delivers toxins to tumor cells) in Phase I/II and Phase II clinical trials for advanced solid tumors and metastatic pancreatic cancer. Bicycle Therapeutics also collaborates with partners to explore applications in additional disease areas beyond oncology.